Contrarius Global Equity Fund’s Thoughts on CRISPR Therapeutics’ (CRSP) Gene Editing Therapy

21 hours ago 1

Soumya Eswaran

Tue, December 30, 2025 astatine 6:40 AM CST 3 min read

Contrarius Investment Management, an concern absorption company, released its third-quarter capitalist missive for the “Contrarius Global Equity Fund”. A transcript of the missive tin beryllium downloaded here. The fund’s capitalist people returned 30.9% successful the September 4th compared to 7.3% for the benchmark MSCI World Index, including reinvested nett income, and 5.5% for the Average Global Equity Fund. The fund’s concern doctrine is autarkic of benchmark considerations, truthful the portfolios typically deviate from the benchmark World Index. Additionally, delight reappraisal the fund’s apical 5 holdings to spot its starring picks successful 2025.

In its third-quarter 2025 capitalist letter, Contrarius Global Equity Fund highlighted stocks specified arsenic CRISPR Therapeutics AG (NASDAQ:CRSP). CRISPR Therapeutics AG (NASDAQ:CRSP) is simply a cistron editing institution that specializes successful processing gene-based medicines for superior quality diseases. The one-month instrumentality for CRISPR Therapeutics AG (NASDAQ:CRSP) was 4.63%, and its shares gained 37.12% implicit the past 52 weeks. On December 29, 2025, CRISPR Therapeutics AG (NASDAQ:CRSP) banal closed astatine $53.97 per share, with a marketplace capitalization of $5.143 billion.

Contrarius Global Equity Fund stated the pursuing regarding CRISPR Therapeutics AG (NASDAQ:CRSP) successful its 3rd 4th 2025 capitalist letter:

"In December 2023, aft astir 6 years of quality objective trials, the FDA approved the archetypal CRISPR-Cas9 cistron editing therapy. This therapy is CRISPR Therapeutics AG's (NASDAQ:CRSP) attraction for sickle compartment disease.